ERBB2 and breast cancer: After the breakthrough of trastuzumab,12 other compounds targeting ErbB members including pertuzumab,13, 14 trastuzumab emtansine,15 and pyrotinib8 have been confirmed to be effective in HER2‐positive patients with metastatic BC.